Seroprevalence of Bartonella spp. infection in HIV patients in Catalonia, Spain

Immaculada Pons*1,2, Isabel Sanfeliu3, María Mercedes Nogueras1, Montserrat Sala1, Manuel Cervantes1, M José Amengual3 and Ferran Segura1,2

Address: 1Infectious Diseases Program, Hospital de Sabadell Institut Universitari Parc Taulí UAB, Sabadell, Spain, 2Medicine Department, Universitat Autonoma de Barcelona, Barcelona, Spain and 3UDIAT Diagnostic Center Laboratory, Sabadell, Spain

Email: Immaculada Pons* - ipons@tauli.cat; Isabel Sanfeliu - isanfeliu@tauli.cat; María Mercedes Nogueras - mnogueras@tauli.cat; Montserrat Sala - msala@tauli.cat; Manuel Cervantes - mcervantes@tauli.cat; M José Amengual - mjose@tauli.cat; Ferran Segura - fsegura@tauli.cat

* Corresponding author

Abstract

Background: Although the first clinical descriptions of Bartonella infection were associated with immunocompromised patient with bacillary angiomatosis, we currently know that this organism is directly involved in diseases affecting a large number of patients, regardless of their immune status. Cat scratch disease, hepatic peliosis, and some cases of bacteraemia and endocarditis, are directly caused by some species of the genus Bartonella. The purpose of this study was to determinate the prevalence of IgG antibodies against Bartonella henselae and B. quintana in HIV patients and to identify the epidemiological factors involved.

Methods: Serum samples were collected from HIV patients treated at Hospital de Sabadell. Antibodies to B. henselae and B. quintana from 340 patients were examined by indirect immunofluorescence assay (IFA). Significance levels for univariate statistical test were determined by the Mann-Whitney U test and \( \chi^2 \) test.

Results: Of 340 patients, 82 were women and 258 men, with a median age of 42.21 ± 10.35 years (range 16–86 years). Seventy-six (22.3%) patients reacted with one or more Bartonella antigens. Of all the factors concerning the seroprevalence rate being studied (age, sex, intravenous drugs use, alcohol consumption, CD4 levels, AIDS, HCV, HBV, residential area), only age was statistically significant.

Conclusion: A high percentage of HIV patients presents antibodies to Bartonella and is increasing with age.
recently identified as responsible for a few cases of human infections [5-10]. Cat scratch disease (CSD), hepatic peliosis and some cases of bacteraemia and endocarditis are directly caused by some species of the genus Bartonella [11-14]. To determine the real incidence of Bartonella infections, we must study the seroprevalence in the general population and the principal reservoirs and vectors of infection transmission. The results yielded by different studies on seroprevalence vary depending on the type of population under study; thus, the research conducted on collective groups that present special characteristics or associated risk factors present a higher prevalence than that found in studies carried out on the normal population.

In patients with addiction to parenteral drugs, it ranged from 15% to 47.5% [15,16]; in patients with HIV infection, it varied between 17.3% and 40% [17,18]. The objective of this study was to evaluate the prevalence of Bartonella infections in patients with HIV in our catchment area and to assess related factors.

**Methods**

**Geographical area**
The study was undertaken in Vallès Occidental (Catalonia), a predominantly urban area near the coast in the northeast of Spain.

**Samples**
The collection of samples took place over a 10-month period, from October 2004 to July 2005. The sample included adults and children treated at Hospital de Sabadell (Vallès Occidental, an area near Barcelona, Spain), where most of the patients diagnosed with HIV from the region are treated (cathment area 407,763 inhabitants). They were attended in periodical CD4 follow-up. Serum samples were collected from these patients at their scheduled follow up visits. The residential area was determined considering the number of inhabitants who lived in the municipalities. In fact, municipalities with < 50,000 inhabitants were considered semirural areas, and >50,000 were regarded as urban areas. Demographic information was obtained from computerized clinic record. Information about alcoholism, drug use, CD4 levels, HCV and HBV serology, was available from computerized records for patients who regularly received care at the clinic and was obtained by chart review for some patients. Informed consent was obtained from adult participants and from the parents of minors.

**Serological technique**
The sample of heparinized blood was sedimented (centrifugation of 5 ml samples of blood at 1,500 rpm for 10 minutes), and the supernatant was collected and stored at -80°C until used. Human serum samples were evaluated by indirect immunofluorescence assay (IFA). We used commercial slides (Bartonella IFA IgG, Focus Technologies, Inc., Herndon, VA) to determine antibodies to Bartonella spp. The kit for detecting IgG antibodies that employees Vero cells infected with either B. henselae or B. quintana was used according to the manufacturer’s instructions. The serum samples were initially diluted 1/64. Any serum samples found to be positive at the initial dilution were further titrated. Positive and negative controls were included in each test. We considered specimens showing no fluorescence at IgG titers of 1/64 as negatives and specimens with bright fluorescence in a dilution of 1/64 or greater as positive. The intensity of each specific fluorescent test was subjectively evaluated and independently graded by two of the authors [19].

**Data analysis**
Statistical analysis was performed using statistical package SPSS for Windows, Release 13.0.1 (standard version; SPSS, Inc., Chicago, IL). Significance levels for univariate statistical test were determined by the Mann-Whitney U test, $\chi^2$ test and Fisher exact test. A p value of 0.05 or less was considered to be significant in all statistical tests used.

**Results**
Of the 340 subjects, 82 (24.1%) were women and 258 (75.9%) men. Mean age was 42.21 ± 10.35 years (range 16–86 years). One hundred and ninety four (57%) and 146 (43%) patients lived in urban and semirural-rural areas, respectively. One hundred and ninety-six (57.6%) patients consumed or had consumed intravenous drugs, whilst 97 (28.5%) presented an excessive intake of alcohol. 13.8% of patients presented CD4 levels below or equal to 200 cell/ml at the time of the study. Of all the patients being followed-up, 102 (30%) had been diagnosed with AIDS. 50% of the patients were infected with the hepatitis C virus, whereas only 5% was infected with the hepatitis B virus (Table 1). None of the patients enrolled in this study presented neither a past history of diseases caused by exposure to Bartonella spp nor bartonellosis symptoms. Antibodies to Bartonella species were highly prevalent in this group of HIV patients; 76 (22.3%) of the samples reacted with at least 1 Bartonella antigen, 32 (42.1%) of the positive samples reacted with only B. henselae antigen, one sample (1.3%) reacted with only B. quintana, and 43 (56.6%) with both. In 34 serum samples, the titers obtained did not allow for differentiation between the 2 Bartonella species, as the specimens presented the same titer or one dilution as difference only. In the 9 remaining serum samples, the titers obtained for B. henselae were clearly superior (2 or more dilutions as difference) (Table 2). Fifty-seven patients (75%) were positive at a titer of 1/64, 10 (13.1%) at 1/128, 5 (6.6%) at 1/256, 2 patients (2.6%) at 1/512 and 2 patients (2.6%) were positive at a titer of 1/1024. The antibody titer was
specific for *B. quintana* in one case only, with a titer of 1/128.

24.4% of women and 21.7% of men presented antibodies to *Bartonella* spp. A statistically significant increase of seropositivity against *Bartonella* spp. was observed as patient age increased ($p < 0.05$). Twenty-three (30.2%) patients with positive serology for *Bartonella* presented a past history of alcohol abuse. Of the 76 patients with positive serology, 47 (61.8%) were addicted to parenteral drugs and 22 (28.9%) had, at some time, been diagnosed with AIDS. Thirty-nine patients presented co-infection between *Bartonella* and HCV, whereas in 3 patients it was between *Bartonella* and HBV. No differences were found regarding the way of transmission of the human immunodeficiency syndrome.

**Discussion**

Preliminary estimates of the prevalence of antibody to *Bartonella* among apparently healthy humans range from 5.88% to 24.7% [17,20]. In a study carried out on a healthy population sample from the same area (83 were men and 78 women, and the mean age with positive serology was 45.18 ± 14.26 years), the seroprevalence was 10.6% [21], a figure that is very similar to that reported in other studies. The incidence of *Bartonella*-associated disease among HIV-infected people is less known. The studies carried out show seroprevalence rates that range from 16 to 40% [18,22].

**Table 1: HIV patients description and serologic results**

| Characteristic          | N total (%) (340 patients) | Positive to Bartonella N (%) (76 patients) | Negative to Bartonella N (%) (264 patients) | P-value |
|-------------------------|----------------------------|--------------------------------------------|--------------------------------------------|---------|
| Sex                     |                            |                                            |                                            |         |
| Female                  | 82 (24.1)                  | 20 (26.3)                                  | 62 (24.4)                                  | 0.611   |
| Male                    | 258 (75.9)                 | 56 (73.7)                                  | 202 (78.3)                                 |         |
| Immunitary state        |                            |                                            |                                            |         |
| ≤ 200 cell/ml           | 47 (13.8)                  | 7 (9.2)                                    | 40 (15.2)                                  | 0.368   |
| > 200 cell/ml           | 293 (86.2)                 | 69 (90.8)                                  | 224 (84.8)                                 |         |
| AIDS ¹                  |                            |                                            |                                            |         |
| Yes                     | 102 (30)                   | 22 (28.9)                                  | 80 (30.3)                                  | 0.820   |
| No                      | 238 (70)                   | 54 (71.1)                                  | 189 (69.7)                                 |         |
| Drugs abuse             |                            |                                            |                                            |         |
| Yes                     | 196 (57.6)                 | 47 (61.8)                                  | 149 (56.4)                                 | 0.401   |
| No                      | 144 (42.4)                 | 29 (38.2)                                  | 115 (43.6)                                 |         |
| Alcohol                 |                            |                                            |                                            |         |
| Yes                     | 97 (28.5)                  | 23 (30.2)                                  | 74 (28.0)                                  | 0.704   |
| No                      | 243 (71.5)                 | 53 (69.7)                                  | 190 (72)                                   |         |
| HBV ²,³                 |                            |                                            |                                            | 0.449   |
| HCV ⁴                   |                            |                                            |                                            | 0.795   |
| Municipality (inhab)    |                            |                                            |                                            | 0.667   |
| >50000                  | 194 (57.0)                 | 45 (59.2)                                  | 149 (56.4)                                 |         |
| <50000                  | 146 (43.0)                 | 31 (40.8)                                  | 115 (43.6)                                 |         |
| Transmission group      |                            |                                            |                                            | 0.390   |
| Heterosexual            | 62 (18.2)                  | 11 (14.5)                                  | 51 (19.3)                                  |         |
| Homosexual              | 15 (4.4)                   | 1 (1.3)                                    | 14 (5.3)                                   |         |
| IDU ⁵                   | 194 (57.1)                 | 47 (61.8)                                  | 147 (55.7)                                 |         |
| Bisexual                | 5 (1.5)                    | 2 (2.6)                                    | 3 (1.1)                                    |         |
| Vertical                | 3 (0.9)                    | 0 (0)                                      | 3 (0.9)                                    |         |
| Unknown                 | 61 (18)                    | 15 (19.7)                                  | 46 (17.4)                                  |         |

1: AIDS criteria: Centers for Disease Control and Prevention (CDC) category C; 2: Hepatitis B virus infection; 3: Fisher Exact test; 4: Hepatitis C virus infection; 5: Injection drug user.

**Table 2: Pattern of IgG antibody titers to *B. henselae* and *B. quintana* in the study population (N= 340)**

| B. henselae titers | B. quintana titers | <1/64 | 1/64 | 1/128 | 1/256 |
|--------------------|---------------------|-------|------|-------|-------|
| <1/64              | 264                 | 0     | 1    | 0     |
| 1/64               | 28                  | 29    | 0    | 0     |
| 1/128              | 4                   | 6     | 0    | 0     |
| 1/256              | 1                   | 5     | 0    | 0     |
| 1/512              | 0                   | 1     | 1    | 0     |
| 1/1024             | 0                   | 0     | 1    | 1     |
[13,25-27]. *B. henselae* seroprevalence in cats in our area was 29.6%, this result confirmed the presence of infection in the main reservoir of this microorganism [28].

*B. henselae* infection, as in other infections caused by fastidious bacteria, gives rise for concern given the complexity of the diagnosis and the variety of presenting clinical pictures, mainly in HIV-infected patients [29]. In fact, cutaneous BA lesions can be clinically indistinguishable from Kaposi’s sarcoma, being differentiated by biopsy only. Hepatic disease caused by *Bartonella* can be indistinguishable from others infectious or malignant conditions that cause hypodense lesions demonstrable by abdominal CT [30]. All these factors make serology as a useful tool for the diagnosis of acute infections caused by *Bartonella* spp. However, it must be taken into account that there can be important limitations when dealing with HIV infected patients [31,32]. The serologic response in patients HIV with a good immunological status could be similar to that of the normal population, whereas possibly in situations of advanced immunodepression or in bacillary angiomatosis, the serologic response could show as a false negative [33].

Our study highlights in the first place an antibody seroprevalence of 22.4% to *Bartonella* species in HIV patients, which is superior to that observed in the healthy population [13,19,25], with the exception of that described in some other studies [25]. Some authors consider HIV patients as a risk group for *Bartonella* infection [34,35] (characteristic personal and hygienic habits); however, other authors do not consider this infection risk to be greater [20,34].

In our experience, a previous study carried out on a healthy population sample from the same area show a seropositive rate of 8.6% [21]. This study included 55 children and 161 adults (≥ 18 years). If children were not considered, the seroprevalence was 10.6%. In view of our HIV-infected patients, predominantly adult, seems to be higher, it could be considered HIV-infection as a risk factor.

Taking into account other studies, this difference among populations might be due to the fact that in HIV patients the infection can last longer or that these patients might become in contact more easily with some of the factors that have a direct impact on increased *Bartonella* infection, such as contact with cats (main reservoir of *B. henselae*) [16,17,24] or that they spend most of their time on the street [24,34]. However, these informations are not available in our study. We could attribute the high rate of seropositivity observed to false positives that are not directly due to HIV infection (to date no crossed- reactions have been observed between both); however, there are studies describing crossed reactions with *Coxiella burnetii* [32,35].

On the other hand, other studies suggest that HIV-infected patients present a higher risk of Q fever than immunocompetent patients [36]. The different factors that might play an important role in the transmission of *Bartonella* spp must also be taken into account. 57.6% of seropositive patients were intravenous drug users, these findings are most likely a result of several conditions that are frequent among IVDUs: living conditions with a high probability of close contact with bacteriaemic cats, fleas, lice, and other potential vectors, repeated parenteral exposures, insufficient medical care, and malnutrition [19,33,34,37]. Other studies do not conclude that drug use might play such an important role [20].

An excessive consumption of alcohol constitutes an elevated risk factor for infection, not only for its capacity to physiologically deteriorate regular alcohol abusers (liver alterations, neurological disorders, etc.), but because in the majority of cases drinking can affect people at low socioeconomic levels (homeless) who might be in closer contact with infection-transmitting vectors [38,39].

Of special interest in these patients was to find out whether the risk for infection increased with immunodepression. In our experience, we were unable to detect a greater incidence among patients who had been diagnosed with AIDS at some given time. In like manner, we were also unable to detect a greater infection incidence in patients with levels < 200 lymphocytes CD4/μl, in contrast with what has been reported by some authors who claim that the prevalence of antibodies against *B. henselae* is inversely proportional to the number of CD4 lymphocytes [30,35].

Our study presented only a 13.8% of patients with low CD4 levels, which could significantly alter our results. If we take into account that HIV-induced immunodepression does not appear to significantly modify the serological response to *Bartonella* spp., serology could be useful in the diagnosis of diseases associated with these microorganisms in HIV-infected patients (acute infection and population-based epidemiological studies). PCR techniques might be of help to diagnose *Bartonella* infection in patients who are more immunodepressed, especially when the infection is subclinical. *Bartonella* infections are substantially underrecognized because of their non-specific symptomatology.

**Conclusion**

In conclusion, the seroprevalence of *Bartonella* spp. among HIV infected patients is greater than that of the healthy population of the same area and thus *Bartonella* infection should be considered in HIV patients.
Competing interests
Immaculada Pons, Isabel Sanfeliu, María Mercedes Nogueras, Montserrat Sala, Manuel Cervantes, M José Amengual and Ferran Segura: The authors declare that they have no competing interests.

Authors' contributions
IP carried out the analysis and interpretation of data, serological technique and the preparation and revision of manuscript.

IS participated in the study concept and design, serological technique and revision of manuscript.

MMN participated in the analysis of data and revision of manuscript.

MC participated in acquisition of epidemiological and clinical data.

MC participated in acquisition of epidemiological and clinical data.

MIA participated in the acquisition of data from laboratory.

FS participated in the study concept and design, and revision of manuscript.

Acknowledgements
We acknowledge to Jordi Real for his advice on biostatistics, Gemma Navarro who help us to acquisition information of patients and Anna Veraguas who have submitted samples to us for serological technique.

Financial support: This work was supported by a FIS-0/0598 grant from "Fondo de Investigaciones Sanitarias" (Health Research Fund), Madrid (Spain) and supported in part by "Red Española de Investigación en Patología Infecciosa (REIPI-CO3/14)" (Spanish Network for Research in Infectious Pathology) and "Red Española de Investigación en SIDA (RIS-03/173)" (Spanish AIDS Research Network).

References
1. Stoler MH, Bonfiglio TA, Steigbigel RT, Pereira M: An atypical subcutaneous infection associated with acquired immune deficiency syndrome. Am J Dis Child 1983, 80:714-718.
2. Alsmark CM, Frank AC, Karlberg EO, Legault BA, Ardell DH, Canback B, Eriksson AS, Naslund AK, Handley SA, Huvet M, La Scola B, Holmberg M, Andersson SG: The louse-borne human pathogen Bartonella quintana is a genomic derivative of the zoonotic agent Bartonella henselae. Proc Natl Acad Sci USA 2004, 101:9716-9721.
3. Chomel BB, Boulouis HJ, Breitschwerdt EB: Cat scratch disease and other zoonotic Bartonella infections. J Am Vet Med Assoc 2004, 224:1270-1279.
4. Comer JA, Paddock CD, Childs JE: Urban zoonoses caused by Bartonella, Coxiella, Ehrlichia, and Rickettsia species. Vector Borne Zoonotic Dis 2001;1:91-118.
5. Kosoy M, Murray M, Gilmore RD, Bai Y, Gage KL: Bartonella strains from ground squirrels are identical to Bartonella washoensis isolated from a human patient. J Clin Microbiology 2003, 41:645-650.
6. Johnson G, Ayers M, McClure SC, Richardson SE, Tellier R: Detection and identification of Bartonella species pathogenic for humans by PCR amplification targeting the ribflav synthase gene (ribC). J Clin Microbiol 2003, 41:1069-1072.
7. Kerkhoff FT, Bemans AMC, Zee A Van der, Rothova A: Demonstration of Bartonella grahamii DNA in ocular fluids of a patient with neuroretinitis. J Clin Microbiol 1999, 37:4034-4038.
8. Mansueto P, Di Lorenzo G, Rizzo M, Mazzola G, Alforni M, Battista Rini G, Mansueto S: Bartonellosis. Recent Pros Med 2003, 94:177-185.
9. Avidor B, Graidy M, Efrat G, Leibowitz C, Shapira G, Schattner A, Zimhony O, Giladi M: Bartonella koehleriae, a new cat-associated agent of culture negative human endocarditis. J Clin Microbiol 2004, 42:3462-3468.
10. Raoult D, Roblot F, Rolain JM, Besnier JM, Loulergue J, Bastides F, Chouquet P: First isolation of Bartonella alastica from a valve of a patient with endocarditis. J Clin Microbiol 2004, 44:278-9.
11. Aguirrebengoa K, Benito JR, Montejo M, Bereciartua E, Perez-Irezabal J, Gonzalez-Zarate P: Enfermedad por arañazo de gato: serie de 14 casos. Utilidad diagnóstica de la serología. Enferm Infect Microbiol Clin 1999, 17:15-18.
12. Chomel BB: Cat-Scratch disease and bacillary angiomatosis. Semin Vet Tech 1999, 15(3):107-18.
13. Brouqui P, Lascola B, Roux V, Raoult D: Chronic Bartonella quintana bacteremia in homeless patients. N Eng J Med 1999, 340:184-189.
14. Raoult D, Fourrier PE, Drancourt M, Marme J, Ettienne J, Cossart J, Cacoub P, Poinignon Y, Leclercq P, Sefton AM: Diagnosis of 22 new cases of Bartonella endocarditis. Annals of Internal Medicine 1996, 125:646-652.
15. Ramos JA, Vargas J, Fernandez-Rivera J, Macias J, Mira JA, Pineda JA: Prevalencia de seropositividad para Bartonella spp. en pacientes adictos a drogas por vía parenteral infectados y no infectados por el virus de la inmunodeficiencia humana. Med Clin 2002, 119:565-567.
16. Comer JA, Diaz T, Vlahov D, Monterroso E, Childs J: Evidence of rodent-associated Bartonella and Rickettsiae infections among intravenous drugs users from Central and East Harlem, New York city. Am J Trop Med Hyg 2001, 65(4):855-860.
17. Blanco JR, Otoe JA, Martinez V, Ramalle E, Garcia I, Ibarra V: Serodiagnostia de la infección por Bartonella henselae en pacientes infectados por el VIH. Enferm Infect Microbiol Clin 1999, 17:434-438.
18. Pape M, Kollaras P, Mandravero K, Tsona A, Metallidis S, Nikolaidis P, Pederson NC, Koehler JE: Occurrence of Bartonella henselae and Bartonella quintana among human immunodeficiency Virus-infected patients. Ann NY Acad Sci 2003, 1033:299-301.
19. Zbinden R, Michael N, Sekulovski A, Graevenitz A, Nadal D: Evaluation of commercial slides for detection of immunoglobulin G against Bartonella henselae by indirect immunofluorescence. Eur J Clin Microbiol Infect Dis 1997, 16:648-652.
20. Garcés-García JA, Baquerizo R, Vargas J, Mira JA, Merchant N, Macias J, Pineda JA: Prevalencia de anticuerpos séricos frente a Bartonella spp. En una población sana del área sur de la provincia de Sevilla. Rev Clin Exp 2005, 205:541-544.
21. Pons I, Sanfeliu I, Cardeñosa N, Nogueras MM, Font B, Segura F: Serological evidence of Bartonella henselae infection in healthy people in Catalonia, Spain. Epidemiol Infect 2008, 28:1-5.
22. Yousif A, Farid I, Baig B, Crek J, Olson P, Wallace M: Prevalence of Bartonella antibodies among human immunodeficiency virus infected from Bahrain. Clin Infect Dis 1997, 25:398-9.
23. Koehler JE, Sanchez MA, Garcia CS, Whitfield MJ, Chen FM, Berger TG, Rodriguez-Barradas MC, Le Boit PE, Tappero JW: Molecular epidemiology of Bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med 1999, 337:1876-1883.
24. Guibal F, La Salomière P, Rybojad M, Hadjabria S, Dehen L, Arlet-G: High seroprevalence to Bartonella quintana in homeless patients with cutaneous parasitic infections in downtown Paris. J Am Acad Dermatol 2001, 44:219-223.
25. Koehler JE, Glaser CA, Tappero JW: Rochalimaeaa henselae infection: A new zoonosis with domestic cat as reservoir. JAMA 1994, 271:531-535.
26. Chomel BB, Pederson NC, Koehler JE, Abbott JK, Kasten RW, Floyd-Hawkins KA, Kass PH, Glaser CA: Bartonella henselae prevalence in domestic cats in California: risk factors and associa-
tion between bacteremia and antibody titers. J Clin Microbiol 1995, 33:2445-2450.

27. Tappero JW, Mohle-Boetani J, Koehler JE, Swaminathan B, Berger TG, LeBoit PE, Smith LL, Wenger JD, Pinner RW, Kemper CA, Reingold AL: The epidemiology of bacillary angiomatosis and bacillary peliosis. JAMA 1995, 274:770-775.

28. Pons I, Sanfeliz I, Quesada M, Anton E, Sampere M, Font B, Pita J, Segura F: Prevalence of Bartonella henselae in domestic cats in Catalonia, Spain. Am J Trop Med Hyg 2005, 72:453-457.

29. Sala M, Font B, Sanfeliz I, Quesada M, Pons I, Segura F: Bacillary angiomatosis caused by Bartonella quintana. Ann N Y Acad Sci 2005:302-7.

30. Regnery RL, Childs JE, Koehler J: Infections associated with Bartonella species in persons infected with human immunodeficiency virus. Clin Infect Dis 1995, 21(Suppl 1):S24-S28.

31. Zangwill KM, Hamilton DH, Perkins BA, Regnery RL, Plikaytis BD, Hadler JL: Cat Scratch disease in Connecticut epidemiology, risk factors, and evaluation of a new diagnostic test. N Engl J Med 1992, 326:8-13.

32. Dalton MJ, Robinson LE, Cooper J, Regnery RL, Olson JG, Childs JE: Use of Bartonella antigens for serologic diagnosis of cat-scratch disease at a National Referral Center. Arch intern Med 1995, 155:1670-1676.

33. García-García JA, Vargas J, Mira JA, Vergara-Lopez S, Macías J, Pineda JA: Dinamica de anticuerpos IgG frente a Bartonella spp. En la enfermedad por arañazo de gato y en pacientes asintomáticos infectados por el virus de la inmunodeficiencia humana. Med Clin 2003, 120:949-5.

34. Blanco JR, Otero JA, Martinez V, Ramalle E, Garcia A, Ibarra V: Seroepidemiologia de la infección por Bartonella henselae en un colectivo de riesgo. Rev Clin Esp 1998, 1198:805-809.

35. Comer JA, Flynn C, Russell L, Regnery RL, Vlahov D, Childs JE: Antibodies to Bartonella Species in Inner-city intravenous drugs users in Baltimore. Arch Intern Med 1996, 156:2491-2495.

36. Raoult D, Levy PY, Dupont HT, Chicheportiche C, Tamalet C, Gauguet JA, Saluducci J: Q fever and HIV infection. AIDS 1993, 7:81-86.

37. Zupan S, Poljak M, Avsic-Zupanc T: Prevalence of Bartonella infections in Slovenian intravenous drugs users. Ann N Y Acad Sci 2003, 990:414-418.

38. Jackson La, Spach DH, Kippen DA, Sugg NK, Regnery RL, Sayers MH, Stamm WE: Seroprevalence to Bartonella quintana among patients at a community clinic in Downtown Seattle. J Infect Dis 1996, 173:1023-26.

39. Koehler JE, Sanchez MA, Tye S, Garrido-Rowland CS, Chen FM, Maurer T, Rodriguez-Barradas MC, Le Boit PE, Tappero JW: Prevalence of Bartonella infection among human immunodeficiency virus infected patients with fever. Clin Infect Dis 2003, 37:559-66.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/8/58/prepub